Compared with matched adjacent nontumor samples, TRIM21 protein levels were downregulated in 63% (n = 57 of 90) and 44% (n = 22 of 50) of two different cohorts of tumor samples, respectively (Figure 6A), and in 50% (n = 20 of 40) of a cohort of colorectal cancer samples (Figure 6B). Here, TRIM21 is linked to neoplasm.